Long-term holder here who is also frustrated at the delays and...

Long-term holder here who is also frustrated at the delays and share price. However, I think the company is genuinely on the cusp of great things happening.

In the webinar, Craig placed emphasis on Cardiex creating a new category for itself, referring to central blood pressure (cBP). In many chronic conditions (hypertension, diabetes etc.), there is always a target for managing the disease, such as blood pressure targets in treating hypertension. These targets are set out in major guidelines to guide best medical practice.

Currently, there is no official guideline on cBP targets. The last major change in blood pressure guidelines by the ACC/AHA was in 2017 and an update is due. There is already extensive literature on cBP and with Pulse being accepted into the AMA's VDL, guidelines for cBP will have to be released to guide non-specialist doctors. My feeling is that the ACC/AHA will update their guidelines to include cBP targets when the Pulse is launched and then they do, this will mark the new gold standard for BP management and best medical practice will use cBP targets moving forward. This will essentially change medical practice in managing hypertension globally (Most, if not all, countries base their BP guidelines on ACC/AHA), effectively creating a new 'category' only for Cardiex.

With cardiovascular being the largest disease burden in the world, and cBP the new gold standard for medical practice, I can see why Craig and Niall are literally grabbing as many shares as they legally can now.